BioDelivery Sciences International, Inc. Expected to Post Q3 2020 Earnings of $0.05 Per Share (BDSI)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) – Research analysts at William Blair upped their Q3 2020 EPS estimates for shares of BioDelivery Sciences International in a report released on Tuesday, May 7th. William Blair analyst T. Lugo now forecasts that the specialty pharmaceutical company will post earnings per share of $0.05 for the quarter, up from their previous estimate of $0.03. William Blair also issued estimates for BioDelivery Sciences International’s Q4 2020 earnings at $0.07 EPS.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings data on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.03. BioDelivery Sciences International had a negative net margin of 42.09% and a negative return on equity of 43.40%. The business had revenue of $19.77 million during the quarter, compared to analysts’ expectations of $19.60 million.

BDSI has been the subject of several other reports. Zacks Investment Research cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Friday, January 18th. BidaskClub cut shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of BioDelivery Sciences International in a research note on Friday, March 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of BioDelivery Sciences International in a research note on Friday, March 15th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $5.79.

Shares of BDSI opened at $4.96 on Thursday. The company has a market cap of $433.60 million, a PE ratio of -6.79 and a beta of 0.41. The company has a debt-to-equity ratio of 1.90, a current ratio of 2.88 and a quick ratio of 2.82. BioDelivery Sciences International has a 1-year low of $1.70 and a 1-year high of $5.37.

In other BioDelivery Sciences International news, Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $4.77, for a total value of $38,160.00. Following the transaction, the director now owns 598,254 shares in the company, valued at approximately $2,853,671.58. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Herm Cukier sold 30,285 shares of BioDelivery Sciences International stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $5.07, for a total transaction of $153,544.95. Following the completion of the transaction, the chief executive officer now owns 66,666 shares in the company, valued at approximately $337,996.62. The disclosure for this sale can be found here. Insiders sold a total of 2,078,335 shares of company stock valued at $10,396,895 over the last ninety days. 13.26% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Advisor Group Inc. boosted its holdings in shares of BioDelivery Sciences International by 56.3% in the 4th quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock valued at $40,000 after purchasing an additional 3,943 shares during the last quarter. First Allied Advisory Services Inc. acquired a new position in shares of BioDelivery Sciences International in the 1st quarter valued at $58,000. Means Investment CO. Inc. acquired a new position in shares of BioDelivery Sciences International in the 1st quarter valued at $59,000. Close Asset Management Ltd boosted its holdings in shares of BioDelivery Sciences International by 1,340.0% in the 1st quarter. Close Asset Management Ltd now owns 18,000 shares of the specialty pharmaceutical company’s stock valued at $95,000 after purchasing an additional 16,750 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of BioDelivery Sciences International in the 4th quarter valued at $147,000. Institutional investors own 56.96% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Story: Outstanding Shares, Buying and Selling Stocks

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.